Combinostics at ECR 2023
March 1-5, 2023 | Vienna, Austria
Booth EXPO X1, AIX area AI-36
Attending European Congress of Radiology (ECR) 2023? Schedule some time to learn more about our cNeuro® suite, including the cMRI™ and cDSI™ applications, the pending cPET™ application, industry-first Dementia Differential Analysis report, and new clinically focused cMRI reports for dementia, multiple sclerosis, traumatic brain injuries, and epilepsy.
Our complete AI software solution supports entire patient care pathways of major neurological disorders, including early detection, differentiation of diagnosis, treatment planning, and monitoring.
Using a combination of science and innovative AI technology, we aim to make a difference in the lives of patients with neurological disorders.
Our solutions put the focus on patients by providing objective, reliable insights for confident, evidence-based diagnostic and management decisions. Radiologists are better equipped to support referring clinicians and their patients with credible, validated imaging quantification and unique differential reporting for major neurological disorders.
Presentation in the AI Theatre
Schedule a meeting with our team.
Interested in a demo of our solutions and industry-leading diagnostic and clinically focused reports? Our team will be on the ground and ready to answer your questions.
Chief Executive Officer (CEO)
Go beyond neurological image quantification.
For conditions such as dementia, multiple sclerosis, traumatic brain injury, and epilepsy, our platform supports earlier disease detection; faster, more efficient, differential diagnostic support; longitudinal tracking and prediction of disease progression; and detection and management of side effects.
Our AI solutions include:
Dementia Differential Analysis report
The new Dementia Differential Analysis report is based on MRI data only, using our cDSI application’s proprietary machine learning method that measures the similarity of disease-specific imaging biomarker values from the patient to those from 2,000+ patients with a confirmed neurodegenerative disease.
It provides the probabilities of the following diagnoses for each patient: